NASDAQ:NMTR 9 Meters Biopharma (NMTR) Stock Forecast, Price & News $0.01 -0.01 (-45.45%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$0.01▼$0.0250-Day Range$0.01▼$0.1352-Week Range$0.07▼$6.56Volume10,046 shsAverage Volume315,915 shsMarket Capitalization$172,032.00P/E RatioN/ADividend YieldN/APrice Target$18.35 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About 9 Meters Biopharma (NASDAQ:NMTR) Stock9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.Read More NMTR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NMTR Stock News HeadlinesAugust 16, 2023 | fool.com9 Meters Biopharma (OTC: NMTR.Q)July 18, 2023 | bizjournals.comRaleigh firm joins worrying trend of bankruptcies for drugmakersOctober 1, 2023 | Legacy Research (Ad)Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”July 18, 2023 | reuters.comDrug developer 9 Meters Biopharma files for bankruptcy protectionJuly 18, 2023 | finance.yahoo.comWhy Are 9 Meters Biopharma Shares Nosediving Today?May 30, 2023 | bizjournals.comTemperato resigns as CEO of Raleigh drugmakerMay 30, 2023 | finance.yahoo.com9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel SyndromeMay 28, 2023 | fool.com9 Meters Biopharma (NASDAQ: NMTR)October 1, 2023 | Legacy Research (Ad)Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”May 25, 2023 | uk.finance.yahoo.comNMTR - 9 Meters Biopharma, Inc.May 19, 2023 | msn.comCitigroup Maintains 9 Meters Biopharma (NMTR) Neutral RecommendationMay 15, 2023 | finance.yahoo.com9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023April 5, 2023 | finance.yahoo.com9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for ObesityMarch 30, 2023 | bizjournals.comWhy this Raleigh pharma just cut half its workforceMarch 28, 2023 | finance.yahoo.com9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022March 25, 2023 | seekingalpha.comNMTR 9 Meters Biopharma, Inc.March 22, 2023 | benzinga.com9 Meters Biopharma Stock (NASDAQ:NMTR), Guidance and ForecastMarch 16, 2023 | bizjournals.comRaleigh pharma raises $5M as phase 3 study beginsMarch 15, 2023 | finance.yahoo.com9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMarch 14, 2023 | finance.yahoo.com9 Meters Biopharma Announces $5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq RulesMarch 7, 2023 | finance.yahoo.com9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare ConferenceFebruary 23, 2023 | theguardian.comSuppliers told to remove prepayment meters that were wrongly force-fittedJanuary 31, 2023 | finance.yahoo.com9 Meters Biopharma to Present at the 2023 BIO CEO & Investor ConferenceJanuary 17, 2023 | theguardian.comLabour calls for halt to ‘shameful’ forced installation of prepayment metersJanuary 15, 2023 | theguardian.comMPs warn over forced prepayment meters as cold weather returnsJanuary 14, 2023 | news.yahoo.comEnergy bills: 'I was forced onto a prepayment meter'January 14, 2023 | thetimes.co.ukMillions of families forced to have prepayment gas and electric metersSee More Headlines Receive NMTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 9 Meters Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address NMTR Company Calendar Last Earnings11/15/2021Today9/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NMTR CUSIPN/A CIK1551986 Webwww.9meters.com Phone(919) 275-1933FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Forecast$18.35 High Stock Price Forecast$35.00 Low Stock Price Forecast$1.70 Forecasted Upside/Downside+152,816.7%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-43,770,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-584.97% Return on Assets-159.45% Debt Debt-to-Equity RatioN/A Current Ratio0.59 Quick Ratio0.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / Book0.06Miscellaneous Outstanding Shares14,336,000Free Float13,992,000Market Cap$172,032.00 OptionableOptionable Beta1.36 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMs. Bethany Sensenig C.M.A. (Age 47)M.B.A., Interim CEO & CFO Comp: $525.59kDr. Peter H. R. Green M.D.Clinical & Scientific Advisor and ConsultantMr. Joseph A. Murray M.D.Clinical & Scientific Advisor and ConsultantDr. Ciaran P. Kelly M.D.Clinical & Scientific Advisor and ConsultantDr. Elena Verdu M.D.Ph.D., Clinical & Scientific Advisor and ConsultantMr. Markku Mäki M.D.Ph.D., Clinical & Scientific Advisor and ConsultantDr. William J. Sandborn M.D. (Age 60)Ph.D., Clinical & Scientific Advisor and Consultant Dr. Roger Liddle M.D.Clinical & Scientific Advisor and ConsultantDr. Anthony J. Dimarino Jr.Clinical & Scientific Advisor and ConsultantDr. Brian Gordon Feagan FRCPCM.D., M.P.H., Clinical & Scientific Advisor and ConsultantMore ExecutivesKey CompetitorsPolarityTENASDAQ:PTEIQCalithera BiosciencesNASDAQ:CALAKiromic BioPharmaNASDAQ:KRBPTC BiopharmNASDAQ:TCBPLannettNYSE:LCINView All CompetitorsInsiders & InstitutionsCitadel Advisors LLCSold 11,700 shares on 8/15/2023Ownership: 0.000%Bethany SensenigSold 9,100 sharesTotal: $11,011.00 ($1.21/share)View All Insider TransactionsView All Institutional Transactions NMTR Stock - Frequently Asked Questions Should I buy or sell 9 Meters Biopharma stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 9 Meters Biopharma in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" NMTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NMTR, but not buy additional shares or sell existing shares. View NMTR analyst ratings or view top-rated stocks. What is 9 Meters Biopharma's stock price forecast for 2023? 4 equities research analysts have issued 1-year target prices for 9 Meters Biopharma's stock. Their NMTR share price forecasts range from $1.70 to $35.00. On average, they expect the company's share price to reach $18.35 in the next year. This suggests a possible upside of 152,816.7% from the stock's current price. View analysts price targets for NMTR or view top-rated stocks among Wall Street analysts. How have NMTR shares performed in 2023? 9 Meters Biopharma's stock was trading at $1.26 at the start of the year. Since then, NMTR stock has decreased by 99.0% and is now trading at $0.0120. View the best growth stocks for 2023 here. How were 9 Meters Biopharma's earnings last quarter? 9 Meters Biopharma, Inc. (NASDAQ:NMTR) announced its quarterly earnings results on Monday, November, 15th. The company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by $0.26. When did 9 Meters Biopharma's stock split? 9 Meters Biopharma's stock reverse split before market open on Tuesday, October 18th 2022. The 1-20 reverse split was announced on Tuesday, October 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of 9 Meters Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other 9 Meters Biopharma investors own include Acasti Pharma (ACST), Miragen Therapeutics (MGEN), Bionano Genomics (BNGO), Evofem Biosciences (EVFM), Outlook Therapeutics (OTLK), Tonix Pharmaceuticals (TNXP), Alibaba Group (BABA), Cellectar Biosciences (CLRB), Pfizer (PFE) and Soleno Therapeutics (SLNO). What is 9 Meters Biopharma's stock symbol? 9 Meters Biopharma trades on the NASDAQ under the ticker symbol "NMTR." How do I buy shares of 9 Meters Biopharma? Shares of NMTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is 9 Meters Biopharma's stock price today? One share of NMTR stock can currently be purchased for approximately $0.01. How much money does 9 Meters Biopharma make? 9 Meters Biopharma (NASDAQ:NMTR) has a market capitalization of $172,032.00. The company earns $-43,770,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis. How can I contact 9 Meters Biopharma? 9 Meters Biopharma's mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The official website for the company is www.9meters.com. The company can be reached via phone at (919) 275-1933 or via email at investor-relations@9meters.com. This page (NASDAQ:NMTR) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 9 Meters Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.